Nuvectis Pharma Prices $100 Million Share Offering, Stock Drops

Corporate Action
โดย RTTNews·Read original
Summary · why it matters

Nuvectis Pharma has priced a public offering of 5 million shares at $20.00 per share, expecting gross proceeds of $100 million. The offering is expected to close on or about July 1, 2026, with Cantor acting as sole bookrunner. Underwriters have a 30-day option to purchase up to an additional 0.75 million shares. Proceeds will fund development of NXP100, NXP200, and NXP900, as well as personnel, capital expenditures, and general corporate purposes. In overnight trading, the stock fell 17.67% to $23.49.

Impact on stocks 1

Biotech & Genomic Medicine▼ · 1 stocks
Nuvectis Pharma Inc
NVCT
▼ NegativeCapitalrelevance

Priced $100M share offering dilutes existing shareholders, causing stock drop.

Off-coverage companies 1

Cantor FitzgeraldPrivate▲ Positive
Capitalrelevance

Cantor is sole bookrunner, earning fees from the offering.

© 2026 MarketDXNews